Dec 11 (Reuters) - Eli Lilly said on Thursday its ‌next-generation ​obesity drug helped patients lose ‌an average of 28.7% of ...

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Eli Lilly decreased the prices of Zepbound and ...

Eli Lilly highlighted its drug's effectiveness in helping people lose weight. Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.